Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells

被引:52
作者
Bottone, FG
Martinez, JM
Alston-Mills, B
Eling, TE
机构
[1] NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA
[2] NIEHS, Lab Computat Biol & Risk Anal, NIH, Res Triangle Pk, NC 27709 USA
[3] N Carolina State Univ, Dept Anim Sci, Raleigh, NC 27695 USA
关键词
D O I
10.1093/carcin/bgh016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cox-1 and Cox-2 specific inhibitors exert chemo-preventative activity. However, the exact mechanisms for this activity remain unclear. Increasing evidence suggests that non-steroidal anti-inflammatory drugs regulate gene expression, which may be responsible, in part, for this activity. In this study, human colorectal carcinoma HCT-116 cells were treated with the Cox-1 specific inhibitor SC-560 and the Cox-2 specific inhibitor SC-58125 to evaluate their ability to induce apoptosis, inhibit cell proliferation, inhibit growth on soft agar and modulate gene expression. The Cox-1 specific inhibitor, SC-560 significantly induced apoptosis and inhibited the growth of HCT-116 cells on soft agar, an in vitro assay for tumorigenicity. SC-58125 moderately induced apoptosis and inhibited growth on soft agar at higher concentrations than were required for SC-560. Previously, we reported that the potent chemo-preventative drug sulindac sulfide altered the expression of eight genes including several transcription factors that may be linked to this drug's chemo-preventative activity. HCT-116 cells were treated with various concentrations of SC-560 or SC-58125 and changes in the expression of these eight genes were determined by real-time reverse transcription- polymerase chain reaction. SC-560 modulated mRNA expression of the eight genes studied. In contrast, SC-58125 required similar to5-10-fold higher concentrations to achieve similar degrees of gene modulation in six of eight genes. Changes in protein expression by SC-560 also occurred for five of these genes with antibodies available (NAG-1, ATF3, C/EBPbeta, MAD2 and MSX1). In conclusion, this is the first report to suggest that like sulindac sulfide, the Cox-1 specific inhibitor SC-560 appears to elicit chemo-preventative activity by altering gene expression, while the chemo-preventative effects of SC-58125 are complex and probably work through these and other mechanisms, such as the inhibition of Cox-2.
引用
收藏
页码:349 / 357
页数:9
相关论文
共 49 条
  • [31] Response of Apcmin and A33ΔNβ-cat mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
    Orner, GA
    Dashwood, WM
    Blum, CA
    Díaz, GD
    Li, QJ
    Al-Fageeh, M
    Tebbutt, N
    Heath, JK
    Ernst, M
    Dashwood, RH
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 506 : 121 - 127
  • [32] Msx1 gene overexpression induces G1 phase cell arrest in human ovarian cancer cell line OVCAR3
    Park, J
    Park, K
    Kim, S
    Lee, JH
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) : 1234 - 1240
  • [33] Piazza GA, 1997, CANCER RES, V57, P2452
  • [34] Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms
    Picariello, L
    Brandi, ML
    Formigli, L
    Orlandini, SZ
    Dolara, P
    Caderni, G
    Raimondi, L
    Tonelli, F
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 360 (01) : 105 - 112
  • [35] Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors
    Richter, M
    Weiss, M
    Weinberger, I
    Fürstenberger, G
    Marian, B
    [J]. CARCINOGENESIS, 2001, 22 (01) : 17 - 25
  • [36] A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
    Sandler, RS
    Halabi, S
    Baron, JA
    Budinger, S
    Paskett, E
    Keresztes, R
    Petrelli, N
    Pipas, JM
    Karp, DD
    Loprinzi, CL
    Steinbach, G
    Schilsky, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) : 883 - 890
  • [37] Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
    Sheng, HM
    Shao, JY
    Kirkland, SC
    Isakson, P
    Coffey, RJ
    Morrow, J
    Beauchamp, RD
    DuBois, RN
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) : 2254 - 2259
  • [38] Pharmacological analysis of cyclooxygenase-1 in inflammation
    Smith, CJ
    Zhang, Y
    Koboldt, CM
    Muhammad, J
    Zweifel, BS
    Shaffer, A
    Talley, JJ
    Masferrer, JL
    Seibert, K
    Isakson, PC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) : 13313 - 13318
  • [39] Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
    Taketo, MM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (21): : 1609 - 1620
  • [40] Cyclooxygenase-2 inhibitors in tumorigenesis (Part I)
    Taketo, MM
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (20) : 1529 - 1536